Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MYC | P01106 | 1/20 | 0.47 |
| ▸ | WDR5 | P61964 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | FBP1 | P09467 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6898345 | 0.85 | ALDH1A1 (0.52) | HTTALDH1A1SMN1; SMN2GAAMYC | |
| Bromide SCHEMBL8557369 | 0.84 | ALDH1A1 (0.64) | HTTALDH1A1SMN1; SMN2GAAMAPT | |
| SCHEMBL2312682 | 0.83 | SMN1; SMN2 (0.75) | HTTALDH1A1SMN1; SMN2GAAMYC | |
| SCHEMBL7270583 | 0.83 | ALDH1A1 (0.66) | HTTALDH1A1SMN1; SMN2GAAMAPT | |
| SCHEMBL6598899 | 0.81 | PTGDR2 (0.43) | HTTPTGDR2 | |
| SCHEMBL7459503 | 0.77 | PTGDR2 (0.43) | PTGDR2 | |
| SCHEMBL11863207 | 0.75 | CYP1A2 (0.76) | ALDH1A1CYP1A2PTGDR2 | |
| SCHEMBL29272745 | 0.73 | MYC (0.57) | ALDH1A1SMN1; SMN2GAAMYCWDR5 | |
| SCHEMBL8069327 | 0.72 | MAPT (0.68) | HTTALDH1A1SMN1; SMN2GAAMYC | |
| Hydrochloric Acid SCHEMBL9091055 | 0.72 | SMN1; SMN2 (0.51) | HTTALDH1A1SMN1; SMN2GAAMYC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6806275-B2 | PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION | NIHON NOHYAKU CO., LTD. (JP) | 2004-10-19 | — | — | US | disclosed |
| CN-1166665-C | Arylpiperidine derivatives and use thereof | �ձ��ݶ�ũҩ��ʽ���� | 2004-09-15 | — | — | CN | disclosed |
| US-20020156283-A1 | Arylpiperidine derivatives and use thereof | NIHON NOHYAKU CO., LTD. (JP) | 2002-10-24 | — | — | US | disclosed |
| US-6407121-B1 | DOPAMINE D4 RECEPTOR ANTAGONISTS; PSYCHOLOGICAL AND BRAIN DISORDERS; ALZHEIMER*S DISEASE, SCHIZOPHRENIA; SIDE EFFECT REDUCTION | NIHON NOHYAKU CO., LTD. (JP) | 2002-06-18 | — | — | US | disclosed |
| CN-1290263-A | Arylpiperidine derivatives and use thereof | NIHON NOHYAKU CO LTD (JP) | 2001-04-04 | — | — | CN | disclosed |
| EP-1070715-A1 | ARYLPIPERIDINE DERIVATIVES AND USE THEREOF | Nihon Nohyaku Co., Ltd. (JP) | 2001-01-24 | — | — | EP | disclosed |
| CN-1184478-A | Thiazole derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 1998-06-10 | — | — | CN | disclosed |
| EP-0816362-A1 | THIAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156283-A1 | Arylpiperidine derivatives and use thereof | DRD1, DRD4, DRD2 | HTT 786/4885ALDH1A1 207/4885SMN1; SMN2 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.